LBP AM SA cut its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 386,411 shares of the biopharmaceutical company's stock after selling 14,602 shares during the quarter. LBP AM SA's holdings in Pfizer were worth $9,792,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Clarity Asset Management Inc. bought a new position in Pfizer in the 4th quarter valued at about $27,000. Gould Capital LLC boosted its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares in the last quarter. North Capital Inc. bought a new position in Pfizer in the first quarter valued at approximately $28,000. Bernard Wealth Management Corp. acquired a new position in Pfizer during the fourth quarter valued at approximately $30,000. Finally, Curio Wealth LLC bought a new stake in Pfizer during the fourth quarter worth $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on PFE shares. Citigroup boosted their price target on Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. HSBC lowered their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Wolfe Research raised their price target on shares of Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a research note on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of "Hold" and a consensus price target of $28.55.
Read Our Latest Report on Pfizer
Pfizer Trading Down 0.5%
NYSE:PFE traded down $0.13 on Friday, reaching $25.65. 34,838,317 shares of the stock traded hands, compared to its average volume of 41,792,724. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company's 50 day moving average is $23.89 and its 200-day moving average is $24.80. The firm has a market capitalization of $145.83 billion, a price-to-earnings ratio of 18.59, a price-to-earnings-growth ratio of 0.94 and a beta of 0.58.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period in the prior year, the firm posted $0.82 EPS. The company's quarterly revenue was down 7.8% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.71%. Pfizer's payout ratio is currently 124.64%.
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
